These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 19532139)

  • 1. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.
    Ahmed N; Salsman VS; Yvon E; Louis CU; Perlaky L; Wels WS; Dishop MK; Kleinerman EE; Pule M; Rooney CM; Heslop HE; Gottschalk S
    Mol Ther; 2009 Oct; 17(10):1779-87. PubMed ID: 19532139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells.
    Mata M; Vera JF; Gerken C; Rooney CM; Miller T; Pfent C; Wang LL; Wilson-Robles HM; Gottschalk S
    J Immunother; 2014 Oct; 37(8):407-15. PubMed ID: 25198528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cells redirected to EphA2 for the immunotherapy of glioblastoma.
    Chow KK; Naik S; Kakarla S; Brawley VS; Shaffer DR; Yi Z; Rainusso N; Wu MF; Liu H; Kew Y; Grossman RG; Powell S; Lee D; Ahmed N; Gottschalk S
    Mol Ther; 2013 Mar; 21(3):629-37. PubMed ID: 23070117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
    Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
    Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
    Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
    J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 7. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.
    Nakazawa Y; Huye LE; Salsman VS; Leen AM; Ahmed N; Rollins L; Dotti G; Gottschalk SM; Wilson MH; Rooney CM
    Mol Ther; 2011 Dec; 19(12):2133-43. PubMed ID: 21772253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma.
    Rainusso N; Brawley VS; Ghazi A; Hicks MJ; Gottschalk S; Rosen JM; Ahmed N
    Cancer Gene Ther; 2012 Mar; 19(3):212-7. PubMed ID: 22173710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.
    Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L
    Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.
    Szöőr Á; Tóth G; Zsebik B; Szabó V; Eshhar Z; Abken H; Vereb G
    Cancer Lett; 2020 Aug; 484():1-8. PubMed ID: 32289441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of experimental medulloblastoma following transfer of HER2-specific T cells.
    Ahmed N; Ratnayake M; Savoldo B; Perlaky L; Dotti G; Wels WS; Bhattacharjee MB; Gilbertson RJ; Shine HD; Weiss HL; Rooney CM; Heslop HE; Gottschalk S
    Cancer Res; 2007 Jun; 67(12):5957-64. PubMed ID: 17575166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts.
    Tóth G; Szöllősi J; Abken H; Vereb G; Szöőr Á
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
    Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
    [No Abstract]   [Full Text] [Related]  

  • 15. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
    Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
    Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
    Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
    J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chimeric T cell receptor N29gamma redirect T lymphocytes response specific to p185HER2 in A murine model of metastatic breast cancer].
    Li SP; Urban FA; Macgregor JN; Hughes DP; McDonagh KT
    Ai Zheng; 2004 Nov; 23(11 Suppl):1370-5. PubMed ID: 15566639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
    Klampatsa A; Achkova DY; Davies DM; Parente-Pereira AC; Woodman N; Rosekilly J; Osborne G; Thayaparan T; Bille A; Sheaf M; Spicer JF; King J; Maher J
    Cancer Lett; 2017 May; 393():52-59. PubMed ID: 28223167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.
    Westwood JA; Smyth MJ; Teng MW; Moeller M; Trapani JA; Scott AM; Smyth FE; Cartwright GA; Power BE; Hönemann D; Prince HM; Darcy PK; Kershaw MH
    Proc Natl Acad Sci U S A; 2005 Dec; 102(52):19051-6. PubMed ID: 16365285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
    Park JA; Cheung NV
    J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.